Yu Zhimin, Liu Qinghua, Liao Hao, Shi Juanyi, Zhou Zhenyu, Yan Yongcong, Xu Junyao, He Chuanchao, Mao Kai, Zhang Jianlong, Wang Jie, Xiao Zhiyu
Guandong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Department of hepatobiliary surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
J Gastrointest Oncol. 2022 Apr;13(2):833-846. doi: 10.21037/jgo-21-543.
The aim of the study was to establish and validate a novel prognostic nomogram of cancer-specific survival (CSS) in resected hilar cholangiocarcinoma (HCCA) patients.
A training cohort of 536 patients and an internal validation cohort of 270 patients were included in this study. The demographic and clinicopathological variables were extracted from the Surveillance, Epidemiology and End Results (SEER) database. Univariate and multivariate Cox regression analysis were performed in the training cohort, followed by the construction of nomogram for CSS. The performance of the nomogram was assessed by concordance index (C-index) and calibration plots and compared with the American Joint Committee on Cancer (AJCC) staging systems. Decision curve analysis (DCA) was applied to measure the predictive power and clinical value of the nomogram.
The nomogram incorporating age, tumor size, tumor grade, lymph node ratio (LNR) and T stage parameters was with a C-index of 0.655 in the training cohort, 0.626 in the validation cohort, compared with corresponding 0.631, 0.626 for the AJCC 8th staging system. The calibration curves exhibited excellent agreement between CSS probabilities predicted by nomogram and actual observation in the training cohort and validation cohort. DCA indicated that this nomogram generated substantial clinical value.
The proposed nomogram provided a more accurate prognostic prediction of CSS for individual patients with resected HCCA than the AJCC 8th staging system, which might be served as an effective tool to stratify resected HCCA patients with high risk and facilitate optimizing therapeutic benefit.
本研究旨在建立并验证一种针对接受手术切除的肝门部胆管癌(HCCA)患者的癌症特异性生存(CSS)新型预后列线图。
本研究纳入了一个由536例患者组成的训练队列和一个由270例患者组成的内部验证队列。人口统计学和临床病理变量从监测、流行病学和最终结果(SEER)数据库中提取。在训练队列中进行单因素和多因素Cox回归分析,随后构建CSS列线图。通过一致性指数(C指数)和校准图评估列线图的性能,并与美国癌症联合委员会(AJCC)分期系统进行比较。应用决策曲线分析(DCA)来衡量列线图的预测能力和临床价值。
纳入年龄、肿瘤大小、肿瘤分级、淋巴结比率(LNR)和T分期参数的列线图在训练队列中的C指数为0.655,在验证队列中的C指数为0.626,而AJCC第8版分期系统对应的C指数分别为0.631和0.626。校准曲线显示,列线图预测的CSS概率与训练队列和验证队列中的实际观察结果之间具有良好的一致性。DCA表明该列线图具有显著的临床价值。
与AJCC第8版分期系统相比,所提出的列线图能为接受手术切除的HCCA个体患者提供更准确的CSS预后预测,可作为对接受手术切除的HCCA高危患者进行分层的有效工具,并有助于优化治疗获益。